Skip to main content

Table 1 Baseline patient characteristics (safety analysis set)

From: Safety and efficacy of long-term combination therapy with bezafibrate and ezetimibe in patients with dyslipidemia in the prospective, observational J-COMPATIBLE study

Characteristics

n

mean ± SD/%

Age (years)

659

60.8 ± 13.1

Men (%)

384

58.3

With complications (%)

551

83.6

Concurrent disease

  

 Hypertension (%)

368

55.8

 Diabetes (%)

230

34.9

 Hepatic disease (%)

152

23.1

 Cardiac disease (%)

46

7.0

 Renal disease (%)

20

3.0

Purpose of combination therapy a

  

 Primary prevention (%)

604

91.7

 Secondary prevention (%)

26

3.9

 Unknown (%)

29

4.4

Concomitant medications

  

 Drugs for hypertension (%)

355

53.9

 Drugs for diabetes (%)

163

24.7

 Statin (%)

14

2.1

  1. Data are expressed as mean ± standard deviation or n and percent.
  2. aDefined according to the Guidelines for the Prevention of Atherosclerotic Cardiovascular Disease 2007 [9].